Last reviewed 2026-04-22 · How we verify

Cy-ATG

Cy-ATG is a cytoxan-based anti-thymocyte globulin that depletes T lymphocytes to suppress immune-mediated destruction of bone marrow.

Cy-ATG is a cytoxan-based anti-thymocyte globulin that depletes T lymphocytes to suppress immune-mediated destruction of bone marrow. Used for Aplastic anemia, Bone marrow failure syndromes.

At a glance

Mechanism of action

Cy-ATG combines cyclophosphamide (cytoxan) with anti-thymocyte globulin (ATG), a polyclonal antibody preparation that targets T cells. This combination is used in immunosuppressive conditioning regimens to deplete pathogenic T cells in aplastic anemia and other bone marrow failure syndromes, allowing hematopoietic recovery or facilitating stem cell engraftment.

Approved indications

• Aplastic anemia
• Bone marrow failure syndromes

Common side effects

• Myelosuppression
• Infection
• Serum sickness
• Infusion reactions
• Hemorrhage

Key clinical trials

• Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial (PHASE4)
• Stem Cell Transplantation in Crohn's Disease (PHASE1, PHASE2)
• Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation (PHASE2)
• Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia (PHASE2)
• Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT (PHASE2)
• MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies (PHASE2)
• Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL (PHASE2, PHASE3)
• ATG Plus Low-dose PT-Cy for GVHD Prevention (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.